Less weight gain and hypoglycaemia with once-daily insulin detemir than with NPH insulin in basal-bolus therapy of overweight type 2 diabetes patients: The PREDICTIVE-BMT trial

被引：0

作者：

Montanana, C. Fajardo

Herrero, C. Hernandez

Fernandez, M. Rivas

机构：

[1] Hosp Virgen Macarena, Seville, Spain

[2] Hosp Infantil Luisa, Seville, Spain

来源：

DIABETOLOGIA | 2007年 / 50卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0978

引用

页码：S404 / S404

页数：1

共 50 条

[31] Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes
Philis-Tsimikas, Athena
Charpentier, Guillaume
Clauson, Per
Ravn, Gabriela Martinez
Roberts, Victor Lawrence
Thorsteinsson, Birger
CLINICAL THERAPEUTICS, 2006, 28 (10) : 1569 - 1581
[32] Treatment Intensification by Stepwise Addition of Prandial Insulin Aspart to Once-Daily Basal Insulin Detemir in Subjects with Type 2 Diabetes: The STEPwise™ Trial
Meneghini, Luigi F.
Hermansen, Kjeld
Mersebach, Henriette
Svendsen, Anne Louise
Kumar, Sudhesh
DIABETES, 2010, 59 : A199 - A199
[33] Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE™ study (vol 62, pg 1971, 2008)
Sreenan, S.
Virkamaki, A.
Zhang, K.
Hansen, J. B.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (01) : 178 - 180
[34] The Effect of Type and Daily Doses of Insulin to Treatment Success in Type 2 Diabetes Patients who are Receiving Basal-bolus Insulin Therapy
Ozturkmen, Yuksel Asli
Avci, Suna
Calim, Aslihan
Cetin, Elif Guven
Demir, Nazan
Mazi, Emrah Erkan
Borlu, Fatih
Altuntas, Yuksel
MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL, 2020, 54 (04): : 416 - 423
[35] Indian Patients with Diabetes Experienced Better Glycemic Control, Less Weight Gain and Hypoglycaemia with Insulin. Detemir When Switched from NPH and Insulin Glargine in PREDICTIVE™ Study
Kesavadev, Jothydev
Singh, Parminder
Pitle, Shailesh Umakant
Bhttacharyya, Arpandev
Mayya, Raghavendra
Moharana, Ashok Kumar
Pathak, Ankit
Kalra, Sanjay
DIABETES, 2009, 58 : A528 - A528
[36] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Häuser, C
Roze, S
DIABETOLOGIA, 2005, 48 : A334 - A334
[37] Study of once-daily Levemir (SOLVE™) 3: safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral antidiabetic therapy
Ross, S. A.
Dzida, G.
Ligthelm, R. J.
DIABETOLOGIA, 2011, 54 : S422 - S423
[38] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Palmer, AJ
Roze, S
DIABETES, 2005, 54 : A609 - A609
[39] Insulin detemir results in less weight gain than NPH insulin when added to oral agents in type 2 diabetes, with this advantage increasing with baseline obesity
Hermansen, K
Tamer, SC
DIABETOLOGIA, 2005, 48 : A4 - A5
[40] The advantage of less weight gain increases with baseline obesity when insulin detemir rather than NPH insulin is added to oral agents in type 2 diabetes
Hermansen, K
Tamer, SC
DIABETES, 2005, 54 : A67 - A67

← 1 2 3 4 5 →